Citigroup Inc Denali Therapeutics Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 44,551 shares of DNLI stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,551

Previous 382,416 88.35%

Holding current value

$1.2 Million

Previous $7.85 Million 86.82%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$14.96 - $23.22 $5.05 Million - $7.85 Million	-337,865 Reduced 88.35%	44,551 $1.03 Million
Q1 2024 May 10, 2024	BUY	$15.83 - $23.35 $3.82 Million - $5.63 Million	241,140 Added 170.69%	382,416 $7.85 Million
Q4 2023 Feb 09, 2024	BUY	$16.2 - $23.18 $48,065 - $68,775	2,967 Added 2.15%	141,276 $3.03 Million
Q3 2023 Nov 09, 2023	BUY	$20.63 - $30.17 $624,717 - $913,607	30,282 Added 28.03%	138,309 $2.85 Million
Q2 2023 Aug 10, 2023	SELL	$23.37 - $32.96 $2.34 Million - $3.31 Million	-100,313 Reduced 48.15%	108,027 $3.19 Million
Q1 2023 May 11, 2023	BUY	$21.91 - $32.67 $1.76 Million - $2.62 Million	80,220 Added 62.61%	208,340 $4.8 Million
Q4 2022 Feb 09, 2023	SELL	$26.28 - $33.92 $1.7 Million - $2.19 Million	-64,522 Reduced 33.49%	128,120 $3.56 Million
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $2.1 Million - $3.11 Million	80,828 Added 72.29%	192,642 $5.91 Million
Q2 2022 Aug 10, 2022	BUY	$20.88 - $35.19 $1.6 Million - $2.69 Million	76,430 Added 216.0%	111,814 $3.29 Million
Q1 2022 May 12, 2022	SELL	$29.0 - $47.27 $2.46 Million - $4.02 Million	-84,997 Reduced 70.61%	35,384 $1.14 Million
Q4 2021 Feb 10, 2022	BUY	$42.59 - $55.02 $483,652 - $624,807	11,356 Added 10.42%	120,381 $5.37 Million
Q3 2021 Nov 10, 2021	BUY	$48.48 - $78.23 $5.29 Million - $8.53 Million	109,025 New	109,025 $5.5 Million

Others Institutions Holding DNLI

# of Institutions

216

Shares Held

115M

Call Options Held

127K

Put Options Held

38.3K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.6B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account